NEW YORK (GenomeWeb News) — GnuBio said today that it is collaborating with the Montreal Heart Institute to develop a genetic panel that will run on the GnuBio platform and predict the risk of sudden cardiac death.
The partners plan to use GnuBio's microfluidics-based sequencing system to develop and validate a set of genes related to sudden cardiac death. "The result will be a clinically validated test the can be used to assess the risk of SCD in susceptible patients on a sequencing platform that will significantly reduce the time from patient to result," the company said in a statement.
As reported by GenomeWeb Daily News sister publication In Sequence, GnuBio plans to launch its sequencer commercially in the second quarter of this year. The system will have a list price of $50,000 and the turnaround time for a targeted sequencing run is expected to be around two hours.
The Montreal Heart Institute is an early-access customer for the GnuBio sequencer. It received the system last summer.